Mirati Announces Latest Results of KRAS Inhibitor on ASCO for the Treatment of Non-Small Cell Lung Cancer

▎WuXi AppTec Content Team Editor Yesterday, Mirati Therapeutics announced that its KRAS G12C inhibitor adagrasib has achieved positive results in a Phase 2 clinical trial in patients with previously treated non-small cell lung cancer harboring a KRAS G12C mutati.
Currently adagrasib is under review by the US F.
Zai Lab has the exclusive rights to develop and commercialize this innovative therapy in Greater Chi.
Adagrasib is a highly specific and potent oral KRAS G12C inhibitor optimized for durable target inhibiti.
Adagrasib has a half-life of up to 24 hours, broad tissue distribution, and its ability to cross the blood-brain barrier, helping to maximize drug effica.
In June last year, the.

Food and Drug Administration granted it breakthrough therapy designation for the treatment of previously treated non-small cell lung cancer patients with the KRAS G12C mutati.
▲Design features of Adagrasib (Image source: Mirati's official website) As of October 15, 2021, among 112 evaluable patients, the objective response rate was 43% and the disease control rate was 8
The median duration of response was 5 months (95% CI, 2-18), and the median progression-free survival was 5 mont.
As of January 15, 2022, the median overall survival was 16 mont.
The company also published results from a retrospective exploratory analysis of a subset of patients with stable, previously treated central nervous system (CNS) metastases in the Phase 2 clinical tri.
In this patient subgroup, adagrasib demonstrated an intracranial objective response rate of 33% and an intracranial disease control rate of 8
In terms of safety, the safety profile of adagrasib in this study was similar to previous reports, and no new safety signals were identifi.
The most common treatment-related adverse events (TRAEs) were gastrointestinal events and exhausti.
The majority were grades 1-2 (53%), with grades 3-4 TRAEs occurring in 43% of patients and grade 5 TRAEs in 2 patien.
TRAE led to discontinuation of treatment in 7% of patien.
"This positive data further supports the scientific basis forthe use of adagrasib to target the KRAS G12C mutation ," said Alexander.
Spira, MD, of the Virginia Cancer Specialists Research Institu.
Positive clinical activity was shown in a characteristic subgroup, including treated patients with stable CNS metastase.
"Reference: [1] Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Canc.
Retrieved May 26, 2022, from https://.
mira.
com/press- releases/press-release-details/2022/Investigational-Adagrasib-Delivers-Positive-Results-in-Registration-Enabling-Study-of-Patients-with-KRASG12C-Mutated-Advanced-Non-Small-Cell-Lung-Cancer/ defau.
aspx Disclaimer: The WuXi AppTec content team focuses on introducing the progress of global biomedical health resear.
This article is for information exchange purposes only, and the views in this article do not represent WuXi AppTec's position, nor do they support or oppose the views expressed in this artic.
It is not a treatment plan recommendati.
If you need treatment plan guidance, please go to a regular hospital for treatme.